Page last updated: 2024-08-21

quinazolines and byl719

quinazolines has been researched along with byl719 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (66.67)24.3611
2020's3 (33.33)2.80

Authors

AuthorsStudies
Ambrosini, G; de Stanchina, E; Musi, E; Schwartz, GK1
Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y1
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A1
Krop, IE; Lin, NU; Liu, P; Roberts, TM; Spangle, JM; Von, T; Wang, Q; Winer, EP; Zhao, JJ1
Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ1
Liu, P; Xu, B; Zhang, C1
Danzer, SC; Gross, C; MacLeod, MC; Tiwari, D; White, AR1
Abramson, VG; Ayers, GD; Chen, SC; Mayer, IA; Richmond, A; Saleh, N; Yan, C; Yang, J1
Chang, X; Chen, Y; Ding, L; He, Y; Lei, C; Ma, C; Tang, Q; Xiao, Z; Yu, Y; Zhang, H; Zhu, Y1

Other Studies

9 other study(ies) available for quinazolines and byl719

ArticleYear
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Silencing; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Pyrroles; Quinazolines; RNA Interference; Signal Transduction; Thiazoles; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays

2014
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
    Cancer research, 2014, Jun-15, Volume: 74, Issue:12

    Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays

2014
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Oncogene, 2016, 07-07, Volume: 35, Issue:27

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice, Knockout; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays

2016
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Nov-10, Volume: 112, Issue:45

    Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles

2015
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:11

    Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays

2016
PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes.
    Neurobiology of disease, 2020, Volume: 144

    Topics: Adenine; Animals; Cerebral Cortex; Class I Phosphatidylinositol 3-Kinases; Epilepsy; Female; Hippocampus; Male; Megalencephaly; Mice; Neurons; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Seizures; Thiazoles

2020
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
    International journal of molecular sciences, 2021, May-14, Volume: 22, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Granulocytes; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines; Tumor Microenvironment; Xenograft Model Antitumor Assays

2021
BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
    BMC cancer, 2023, Aug-08, Volume: 23, Issue:1

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines

2023